Soleus Capital Management’s Neuropace NPCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$38.6M Buy
2,932,207
+228,999
+8% +$3.44M 1.56% 19
2025
Q4
$41.7M Sell
2,703,208
-254,749
-9% -$3.41M 1.54% 17
2025
Q3
$30.5M Buy
2,957,957
+645,000
+28% +$6.08M 1.54% 23
2025
Q2
$25.8M Sell
2,312,957
-295,211
-11% -$3.69M 1.71% 19
2025
Q1
$32.1M Buy
2,608,168
+175,000
+7% +$2.19M 2.31% 12
2024
Q4
$27.2M Hold
2,433,168
1.71% 18
2024
Q3
$17M Hold
2,433,168
1.31% 27
2024
Q2
$18.4M Hold
2,433,168
1.62% 23
2024
Q1
$32.1M Hold
2,433,168
2.38% 9
2023
Q4
$25.1M Sell
2,433,168
-33,037
-1% -$263K 2.78% 14
2023
Q3
$24M Sell
2,466,205
-9
-0% -$53 2.21% 13
2023
Q2
$11.1M Buy
2,466,214
+37,500
+2% +$170K 1.23% 23
2023
Q1
$11.3M Buy
2,428,714
+59,711
+3% +$229K 1.17% 27
2022
Q4
$3.53M Buy
2,369,003
+35,000
+1% +$77.8K 0.51% 46
2022
Q3
$8.75M Hold
2,334,003
1.19% 26
2022
Q2
$11.6M Buy
2,334,003
+10,000
+0.4% +$66K 1.8% 19
2022
Q1
$19.1M Buy
2,324,003
+15,000
+0.6% +$129K 2.46% 12
2021
Q4
$23.3M Buy
2,309,003
+638,867
+38% +$8.3M 2.33% 11
2021
Q3
$26.5M Buy
1,670,136
+285,749
+21% +$6M 4.13% 6
2021
Q2
$32.9M Buy
+1,384,387
New +$32.1M 5.06% 4

Other funds holding NPCE

Soleus Capital Management's NPCE Position: Q1 2026 in Review

Soleus Capital Management increased its Neuropace (NPCE) stake by 8.5% in Q1 2026, buying an estimated $3.44M and bringing the position to 2,932,207 shares worth $38.6M. The position accounts for 1.56% of the portfolio, ranked #19.

Soleus Capital Management first reported a position in NPCE in Q2 2021 and has held it in 20 quarters since. The position peaked at $41.7M in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Soleus Capital Management held 2,932,207 shares of Neuropace worth $38.6M as of Q1 2026.
  • Soleus Capital Management bought 228,999 Neuropace shares in Q1 2026, an estimated $3.44M.
  • Neuropace made up 1.56% of Soleus Capital Management's portfolio in Q1 2026, its #19 holding.
  • Soleus Capital Management first reported a position in Neuropace in Q2 2021 and has held it in 20 quarters since.
  • Soleus Capital Management's Neuropace position peaked at $41.7M in Q4 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.